Inspiring solutions for a better tomorrow drive the success of our group. We have established ourselves as an innovative private investor by placing people at the forefront. The drive towards "people empowerment" catapulted our expansion from niche investor to the global investment group we are today. From innovative software and semiconductor technologies to biotech therapeutics, people across the world - entrepreneurs, partners, customers and communities at large - experience our vision for a better tomorrow
We have grown our portfolio of Bridgewest Group companies with smart, motivated people. Collaborative mentorship and capital infusion move the brightest entrepreneurs forward. Beginning with idea inception and all the way through exit, our seasoned team of operating partners and subject matter experts guide entrepreneurs to successful financial outcomes. As private investors, we are not beholden to other investors and artificial timeframes. This allows us to maximize outcomes for everyone based on merit instead of timeline adherence. Our robust eco-community facilitates functional support so CEOs can turn their ideas into prosperous companies. Those with vision, skill and determination enjoy long tenure with our teams. Nearly 100% of portfolio company CEOs stay on to form new ventures within the Bridgewest Group after successful exits.
Learn more about our company through our showcase pages and our team.
We have grown our portfolio of Bridgewest Group companies with smart, motivated people. Collaborative mentorship and capital infusion move the brightest entrepreneurs forward. Beginning with idea inception and all the way through exit, our seasoned team of operating partners and subject matter experts guide entrepreneurs to successful financial outcomes. As private investors, we are not beholden to other investors and artificial timeframes. This allows us to maximize outcomes for everyone based on merit instead of timeline adherence. Our robust eco-community facilitates functional support so CEOs can turn their ideas into prosperous companies. Those with vision, skill and determination enjoy long tenure with our teams. Nearly 100% of portfolio company CEOs stay on to form new ventures within the Bridgewest Group after successful exits.
Learn more about our company through our showcase pages and our team.
Location: United States, California, San Diego
Employees: 11-50
Founded date: 1999
Investment Type: Venture Capital
Mentions in press and media 14
| Date | Title | Description |
| 02.07.2024 | Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board | PERTH, Australia, July 2, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, global pharmaceutical holding company with NovaCina CDMO division and LumaCina pharmaceutical supply division, announces the addition of renown Australian executive Joh... |
| 31.05.2024 | LumaCina announces availability of Oral Morphine pain medication for New Zealanders | PERTH, Australia and MIAMI, May 31, 2024 /PRNewswire/ -- LumaCina, the pharmaceutical supplier and marketing division of Bridgewest Perth Pharma announce new production of Oral Morphine to meet critical drug shortage in New Zealand. The sho... |
| 06.03.2024 | Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision | Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCi... |
| 24.10.2023 | Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma | --Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufact... |
| 17.10.2023 | Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion | SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors ... |
| 14.09.2023 | Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices | MIAMI and AUCKLAND, New Zealand, Sept. 14, 2023 /PRNewswire/ -- Avasa, a medical device pioneer advancing surgical techniques for improved patient outcomes, announces the successful completion of its recent funding, raising an impressive $1... |
| 26.04.2023 | Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit | MIAMI and PERTH, Australia, April 26, 2023 /PRNewswire/ -- Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, establishes LumaCina business unit under ... |
| 05.04.2023 | Bridgewest Group launches NovaCina, new sterile injectable CDMO | MIAMI and PERTH, Australia, April 4, 2023 /PRNewswire/ -- Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, launches new Contract Development and Manu... |
| 05.04.2023 | Bridgewest Group launches NovaCina, new sterile injectable CDMO | MIAMI and PERTH, Australia, April 5, 2023 /PRNewswire/ -- Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, launches new Contract Development and Manu... |
| 04.04.2023 | Bridgewest Group completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer | MIAMI and PERTH, Australia, April 4, 2023 /PRNewswire/ -- Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, announces that it has completed the acquis... |
Show more